BioLargo shareholders approve increase in authorized shares to 550M and authorize reverse stock split

BIOLARGO, INC.

Authorized common shares increased from 400M to 550M, effective June 7, 2022.
Board authorized to implement a reverse stock split at a ratio between 1:4 and 1:25 at its discretion.
All seven director nominees elected; advisory say-on-pay passed with 84.3M for, 9.8M against.
Ratification of Haskell & White LLP as auditor for FY2022 approved with 151.2M for.
Reverse split proposal passed with 136.2M for, 16.7M against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.